Project Grant R34MH135746
Award Date
8/1/24
Completion Date
7/31/27
Dollars Obligated
$702K
Funding Federal Agency
National Institute of Allergy and Infectious Diseases
Awarding Federal Agency
National Institute of Mental Health
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Milwaukee, WI 53226, USA
Similar Awards
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to implement an innovative HIV self-testing and long-acting injectable HIV treatment and prevention intervention for commercial minibus drivers in Nigeria. The $809,692 award to The George Washington University, with sub-awards to Wake Forest University Health Sciences, University of Rochester, Emory...
This federal Project Grant award of $146,922 from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) supports research to identify patient-level implementation determinants related to long-acting injectable HIV pre-exposure prophylaxis (PrEP) among young men who have sex with men (YMSM) living in rural areas. The award will fund a convergent mixed methods study conducted by the Medical College of Wisconsin, Inc. to understand rural YMSM's...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $381,487 to the University of Maryland, Baltimore (UMB) to assess the early implementation of long-acting injectable cabotegravir (CAB-LA) pre-exposure prophylaxis (PrEP) among adolescent girls and young women (AGYW) at high risk of HIV acquisition in Zambia. The key objectives are to: 1) Evaluate implementation determinants of CAB-LA...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $911,400 Project Grant to Emory University to establish the PREMISE (PrEP Epidemiology, Modeling, and Surveillance) system. The goal is to use national PrEP prescription data, legal/policy coding, and natural experimental designs to inform the U.S. HIV epidemic response and understand which programs and policies are effective at facilitating...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,233,520 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Johns Hopkins University. The goal of this 5-year project, titled "CHIPP-PREP: Cabotegravir-Hormone Interrogation of Pharmacokinetics/Pharmacodynamics for HIV Prevention in Cisgender and Transgender Persons," is to characterize the relationship between gender-affirming hormone therapy and long-acting...
This Project Grant award of $2,155,836.00 was made by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award supports a 5-year hybrid implementation-effectiveness randomized controlled trial (RCT) comparing two strategies to engage the social networks of current PrEP clients in Miami-Dade County, Florida to increase equitable reach of HIV self-testing (HIVST) and PrEP information. The study, titled...
This $715,041 Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) will support research to understand real-world choices, preferences, and outcomes related to the roll-out of oral and long-acting injectable PrEP (pre-exposure prophylaxis) among women in Malawi. The study, titled "Better Info on Women's PrEP Choices and Outcomes in Malawi", has three specific aims: 1) Evaluate longitudinal patterns of oral...
This Project Grant award of $1,681,276 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund a study to identify preferences and care components to optimize the delivery of long-acting injectable (LAI) PrEP for sexual minority men (SMM) who use methamphetamine in the U.S. The study will leverage an existing cohort to first conduct qualitative interviews with SMM who use methamphetamine and healthcare providers, then...
This Project Grant award of $1,260,020, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support a 3-year pilot study to assess the acceptability, feasibility, appropriateness, and preliminary effects of integrating an evidence-based mental health intervention for transgender and gender-diverse individuals affected by violence and HIV in Los Angeles County. The study will leverage an...
This Project Grant award from the National Institutes of Health's Trans-NIH Research Support program (CFDA 93.310) provides $844,564 to Emory University to conduct formative research and develop an implementation strategy to link adolescent girls and young women in South Africa who experience intimate partner violence (IPV) with access to pre-exposure prophylaxis (PrEP) options, including long-acting modalities. The award period is from August 1, 2024 to July 31, 2026. The goal is to optimize...